The FDA approved a supplemental application for Keytruda (pembrolizumab) on June 17, 2024. This approval pertains to the efficacy of the drug, indicating an expansion of its approved uses. The sponsor for this application was MERCK SHARP DOHME.
Background
Pembrolizumab (Keytruda) is a well-known immunotherapy agent. This supplemental approval, granted on June 17, 2024, specifically addresses an expansion of the drug's approved indications based on new efficacy data. The sponsor, MERCK SHARP DOHME, submitted the application (BLA 125514 S-155) to the FDA, leading to this update.
What this means
This supplemental approval for Keytruda (pembrolizumab) based on efficacy signifies that the drug's prescribing information has been updated to include a new or expanded indication or patient population where its effectiveness has been demonstrated. Such approvals are a standard process for drugs that show benefit in additional clinical settings beyond their initial authorization. Healthcare professionals should refer to the official prescribing information released by the FDA to understand the specific details of this expanded efficacy claim, including the precise patient population, dosing, and any associated safety considerations. This update provides clinicians with additional options for utilizing Keytruda in patient care, reflecting ongoing research and development efforts by the sponsor, MERCK SHARP DOHME.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for BLA 125514 S-155, categorized as an efficacy update, was granted on June 17, 2024, and is accessible via accessdata.fda.gov.